10 Oct 2025Open access
A Comparison of Vitrectomy with and without Intravitreal Methotrexate for Advanced Proliferative VitreoretinopathyPublisher siteJournal of the West African College of Surgeons, Retinal and Macular Surgery
Active, last published 2026
In retinal and macular surgery
Ogugua Ndubuisi
Okonkwo
Scholar“Research focused on Retinal and Macular Surgery and adjacent fields.”
Claim Your Profile1
H-index
9
Citations
Ogugua has not officially claimed their profile. If you are Ogugua, claim it free.
Claim Your Profile
Pioneer
LOCKED
Pathfinder
LOCKED
Scholar
EARNED
Innovator
LOCKED
Inventor
LOCKED
Catalyst
LOCKED
Expert
UPGRADE
01 · About the work
What I study
gugua Ndubuisi Okonkwo is a researcher working on Retinal and Macular Surgery. A fuller summary will appear once they update their profile.
02 · Reach
Publication output and reach
Ogugua's work has been cited 9 times across 2 active years. Bars show publications per year; the line shows cumulative citation totals across publications first appearing in each year.
03 · Research focus
Topics
Retinal and Macular Surgery×2Retinal Diseases and Treatments×2Intraocular Surgery and Lenses×1
04 · Where I am
Affiliations
Affiliation on published researchLagos University Teaching Hospital, NigeriaDrawn from the institution listed on this researcher’s published work.
05 · Selected work
Recent publications
2 works1 Jul 2024Open access
Anti-Vascular Endothelial Growth Factor for Treating Diabetic Macular Edema and Diabetic Retinopathy: A Summary of Pivotal Trials and StudiesPublisher siteNigerian Journal of Vitreoretinal Diseases, Retinal Diseases and Treatments
Expert Academic Profiles go further
Citation trend analytics, exportable publication records, and direct enquiry routing from industry and funders.
Are you Ogugua?
Claim it to verify your details, connect with industry partners, and explore Fractional Domain Expert opportunities through MARATTO™.
African researchers are full of potential that too often goes unrecognised. Your MARATTO™ profile gives your work the commercial pathway it deserves.
Claim Your Profile
Free to claim · takes a minute to verify it’s you